Non-steroidal anti-inflammatory drugs amid COVID-19 pandemic: An ally or an enemy?
Bangladesh Journal of Infectious Diseases
; 8(1):50-52, 2021.
Article
in English
| ProQuest Central | ID: covidwho-20237053
ABSTRACT
As the current global pandemic of the novel coronavirus diseases 2019 (COVID-19) continues to rage, the scientific and medical worlds are working to establish an effective therapy against the illness. Recently questions regarding non-steroidal anti-inflammatory drugs (NSAIDs) as a potential therapeutic option for COVID-19 have surfaced. While some studies hint towards the possible benefit of NSAIDs against SARS-CoV-2 infection, the current body of evidence also sheds light on the potential risk of using NSAIDs in COVID-19 patients. Thus, the available literature does not provide conclusive evidence for or against the use of NSAIDs for treating COVID-19 patients. Given the limited data available, we suggest cautionary approaches for the public to avoid possible harm until further evidence emerges. NSAIDs should not be used as the first-line agents for COVID-19 unlessunder medical supervision. Moreover, patients with chronic inflammatory conditions should continue the NSAIDs as per their regular prescriptions.
Medical Sciences--Communicable Diseases; SARS-CoV-2; NSAIDS; ACE2; COVID-19; Infections; Infectious diseases; Medicine; Cytokine storm; Severe acute respiratory syndrome coronavirus 2; Pandemics; Medical research; Internal medicine; Nonsteroidal anti-inflammatory drugs; Health sciences; Illnesses; Anti-inflammatory agents; Clinical outcomes
Full text:
Available
Collection:
Databases of international organizations
Database:
ProQuest Central
Type of study:
Prognostic study
Language:
English
Journal:
Bangladesh Journal of Infectious Diseases
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS